Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian or endometrial cancer that came back after at least 6 months from your last platinum chemotherapy.
- You are a woman 18 years or older.
- You are healthy enough for daily activities (able to care for yourself) and expected to live at least 12 more weeks.
- Your cancer can be seen on a CT scan (measurable or evaluable disease).
- Your blood counts and kidney/liver function are within a certain range (doctors will check).
- You have not had prior treatment with the study drug (sacituzumab govitecan) or similar drugs.
- You must not be pregnant or breastfeeding, and you must use effective birth control during and 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy called Sacituzumab for people with a rare type of ovarian cancer (clear cell carcinoma) whose cancer worsened after immunotherapy. The drug is designed to deliver chemotherapy directly to cancer cells, and researchers want to see if it can help when other treatments stop working.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This trial tests a drug called IMMU-132 (sacituzumab govitecan) for women with advanced or recurrent ovarian cancer that has come back after platinum-based chemotherapy. The drug targets a protein called TROP-2 found on tumor cells, which may help stop the cancer from growing.
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
This trial tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) for women whose ovarian cancer stopped responding to platinum chemotherapy. The goal is to see if the combination helps shrink or slow the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.